What this means
This is a plan for a small study of 60 adults, half getting a treatment and half a placebo. It has not started yet, so no results exist, and it cannot show whether the treatment works or is safe.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 45–65 · 60 adults aged 45 to 65 (not yet started)
- Where
- Not listed
The science
- Registered title
- Study of the Safety and Efficacy of Natural Genome Reconstruction Technology of Hematopoietic Stem Cells in Adult Patients
- Trial ID
- NCT06877377 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Aging
- What is tested
- hDNAgr Therapy, Placebo
- Sponsor
- S.LAB (SOLOWAYS)
- Ages
- 45 Years to 65 Years
- Dates
- First posted Mar 14, 2025 · updated Jul 20, 2025
Registry summary
This pilot randomized, double-blind, placebo-controlled study evaluates the safety and efficacy of the hDNAgr technology aimed at natural genome reconstruction in hematopoietic stem cells in adults aged 45-65. The study hypothesizes that administering fragmented therapeutic double-stranded DNA will safely correct localized genomic damage-including telomere elongation-enhance hematopoietic function by restoring polyclonality and increasing reparative potential, and ultimately rejuvenate blood and bone marrow to potentially lower the patient's biological age. The primary endpoint is safety and tolerability, assessed by the frequency and severity of adverse events, while secondary endpoints focus on telomere length, hematological parameters, aging and inflammation biomarkers, functional health measures, and preliminary biological age evaluations. Sixty participants (30 in the hDNAgr group and 30 receiving placebo) will be observed over a 6-month period with multiple scheduled visits.